Retatrutide activates three metabolic receptors: GLP-1, GIP, and glucagon
The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)
When states end coverage, federal officials can point to them and say it was their decision
Switching GLP-1 medications and how it affects your timeline Switching between GLP-1 medications is increasingly common as patients seek better results, fewer side effects, or respond to availability changes
It may also be used as a maintenance dose after significant weight loss has already been achieved, she added
GLP-1 receptor: a new target for sepsis